Xeris Announces Updates to Its Board of Directors
Chief Executive Officer John Shannon named Chair of the Board
Marla Persky to transition to Lead Independent Director of the Board
Board appoints Nerissa Kreher, M.D., effective July 1, 2026
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as Chief Executive Officer, effective July 1, 2026. Mr. Shannon succeeds Marla Persky, who will remain on the Board as Lead Independent Director. The Company also announced the appointment of Nerissa Kreher, M. D., to its Board of Directors, effective July 1, 2026, expanding the Board to eight members.
